tradingkey.logo

Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma

ReutersDec 23, 2025 6:02 AM

- Sanofi SA SASY.PA:

  • SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMA

  • APPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMONSTRATING DUPIXENT SIGNIFICANTLY REDUCED EXACERBATIONS

  • DUPIXENT REDUCES ASTHMA EXACERBATIONS BY 54%-65%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI